| 1 |
NCT03472183 |
Recruiting |
Exploration of the Enteric Nervous System in Alzheimer Disease |
|
|
Interventional |
Not Applicable |
- Nantes University Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Differences in extracellular deposits of beta-amyloid peptide in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.
- Differences in tau protein in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.
- Differences in neuronal loss in enteric submucosal tissue between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease
- Differences in neuronal Glia cells in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.
|
30 |
All |
50 Years to 80 Years (Adult, Senior) |
NCT03472183 |
RC17_0252 |
SYNEMA |
April 26, 2018 |
April 26, 2020 |
August 25, 2020 |
March 21, 2018 |
April 26, 2018 |
|
- Nantes university Hospital
Nantes, France
|
|
| 2 |
NCT03340571 |
Recruiting |
Blood Biomarker of Alzheimer's Disease (AD) |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Biological marker of Alzheimer's disease
|
60 |
All |
50 Years and older (Adult, Senior) |
NCT03340571 |
Pro00085997 |
|
March 12, 2018 |
August 2018 |
August 2018 |
November 13, 2017 |
March 14, 2018 |
|
- Duke University
Durham, North Carolina, United States
|
|
| 3 |
NCT02022943 |
Recruiting |
Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies |
- Alzheimer's Disease
- Dementia
|
|
Observational |
|
|
Other |
- Observational Model: Other
- Time Perspective: Other
|
- Number of individuals enrolled into Alzheimer's prevention studies
- Number of individuals referred to Alzheimer's prevention research studies / sites
|
500000 |
All |
18 Years to 110 Years (Adult, Senior) |
NCT02022943 |
APR |
APR |
May 2012 |
January 2030 |
January 2030 |
December 30, 2013 |
October 23, 2017 |
|
- Banner Alzheimer's Institute
Phoenix, Arizona, United States
|
|
| 4 |
NCT01692977 |
Completed |
What Elements of the Design of a Healing Garden Are Used as Landmarks by Patients With Alzheimer's Disease to Locate? |
|
- Other: neuropsychological assessment
|
Interventional |
Not Applicable |
- Central Hospital, Nancy, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Analyze nature and frequency of elements of the " art, memory and life " garden used as landmarks by Alzheimer's disease patients
- Study the characteristics of the elements that contributed to decision-making regarding spatial orientation, the cognitive map, correlations between success in experimental, neuropsychological assessment in Alzheimer disease and healthy control subjects.
|
77 |
All |
65 Years to 90 Years (Adult, Senior) |
NCT01692977 |
2011-A00993-38 |
JAZ-TOP |
August 2012 |
October 2014 |
October 2014 |
September 26, 2012 |
July 30, 2015 |
|
- University Hospital of Nancy , Saint Julien Hospital, France
Nancy, France
|
|
| 5 |
NCT03408041 |
Completed |
Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters |
|
- Other: Medical file data extraction
|
Observational |
|
- Murielle Surquin
- Brugmann University Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Age
- Sex
- Ethnic origin
- (and 2 more...)
|
129 |
All |
Child, Adult, Senior |
NCT03408041 |
CHUB-parameters Alzheimer |
|
May 1, 2016 |
October 1, 2017 |
October 1, 2017 |
January 23, 2018 |
January 23, 2018 |
|
- CHU Brugmann
Brussels, Belgium
|
|
| 6 |
NCT01624389 |
Unknown † |
Establish Taiwan Alzheimer's Disease Neuroimaging Initiative - a Three-year Pilot Study |
|
|
Interventional |
Not Applicable |
- Chang Gung Memorial Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: Single (Participant)
- Primary Purpose: Diagnostic
|
- Rate of conversion from NC, EMCI, LMCI to AD.
|
200 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT01624389 |
101-1074A1 |
Alzheimer's |
January 2012 |
January 2015 |
January 2015 |
June 20, 2012 |
June 20, 2012 |
|
- Tzu-Chen-Yen
Taoyuan, Taiwan
|
|
| 7 |
NCT03255720 |
Not yet recruiting |
Application of Diffusion Tensor Imaging in Alzheimer's Disease :Quantification of White Matter Micro-structural Changes |
|
|
Observational |
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- the extent of tissue damage of several brain white matter regions in patients with Alzheimer's disease.
|
40 |
All |
60 Years to 80 Years (Adult, Senior) |
NCT03255720 |
diffusion tensor imaging |
|
September 29, 2017 |
December 1, 2022 |
December 31, 2022 |
August 21, 2017 |
September 26, 2017 |
|
|
|
| 8 |
NCT02986932 |
Recruiting |
Blood-Brain-Barrier Opening Using Focused Ultrasound With IV Contrast Agents in Patients With Early Alzheimer's Disease |
|
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in contrast enhancement (intensity) following BBB disruption
- Change in amyloid uptake
- Adverse events
- (and 5 more...)
|
6 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT02986932 |
AL001 |
BBB-Alzheimers |
December 2016 |
December 2017 |
December 2017 |
December 8, 2016 |
March 28, 2017 |
|
- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
|
|
| 9 |
NCT02703636 |
Recruiting |
Study to Evaluate the Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease |
- Mild to Moderate Alzheimer's Disease
|
|
Interventional |
Phase 4 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline to week 24 in the total score of Mini-Mental State Examination (MMSE)
- Monitoring and recording of all adverse events (AEs) and serious adverse events (SAEs).
- Change from baseline to Week 8 in Mini-Mental State Examination (MMSE) total score.
- (and 5 more...)
|
120 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT02703636 |
CENA713DJP02 |
ENA1stepswitch |
May 10, 2016 |
April 24, 2018 |
April 24, 2018 |
March 9, 2016 |
June 21, 2017 |
|
- Novartis Investigative Site
Fukuoka-city, Fukuoka, Japan - Novartis Investigative Site
Fukuoka-city, Fukuoka, Japan - Novartis Investigative Site
Aizuwakamatsu, Fukushima, Japan - (and 17 more...)
|
|
| 10 |
NCT02672306 |
Active, not recruiting |
Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease |
|
- Biological: UCMSCs
- Biological: Placebo
|
Interventional |
Phase 1
Phase 2 |
- South China Research Center for Stem Cell and Regenerative Medicine
- Guangzhou General Hospital of Guangzhou Military Command of PLA
- The Third Affiliated Hospital, SUN YAT-SEN University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score
- Change in Mini-Mental State Examination (MMSE) Score
- Change in Clinician's Interview-Based Impression of Change (CIBIC-plus) Score
- (and 3 more...)
|
16 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT02672306 |
UCMSC-1 |
SEESUPAD |
October 20, 2017 |
October 2018 |
October 2019 |
February 3, 2016 |
April 26, 2018 |
|
- South China Research Center for Stem Cell and Regenerative Medicine,South China Institute of Biomedicine
Guangzhou, Guangdong, China
|
|
| 11 |
NCT02349191 |
Not yet recruiting |
Omental Transposition Surgery for Mild Alzheimer's Disease |
|
- Procedure: Omental transposition for mild Alzheimers disease
|
Interventional |
Not Applicable |
- Bariatric Medicine Institute, Salt Lake City, UT
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of surgical complications from beginning of anesthesia to discharge from Intensive Care Unit.
- Change in Alzheimer's Disease Assessment Scale - Cognition (ADAS-cog) score from baseline at 12 months.
- Change in Montreal Cognitive Assessment (MoCA) score from baseline at 12 months
- (and 6 more...)
|
25 |
All |
65 Years to 85 Years (Adult, Senior) |
NCT02349191 |
Cottam - 1 |
|
March 2016 |
April 2017 |
May 2019 |
January 28, 2015 |
March 22, 2016 |
|
|
|
| 12 |
NCT02195596 |
Unknown † |
Effects of Exercise on Cognitive Performance of Patients With Alzheimer-type Dementia. Pilot Study. |
|
- Other: High intensity aerobic exercise+strength
- Other: Low intensity aerobic exercise+strength
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Supportive Care
|
- Change in cognitive performance that is measured in a blinded way with the cognitive section of the ADAS scale (Alzheimer's Disease Assessment Scale) at 0, 6 and 12
- Global cognitive performance
|
80 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT02195596 |
2011111100 |
EFA-P |
April 2013 |
January 2015 |
December 2015 |
July 21, 2014 |
July 21, 2014 |
|
- Galdakao Hospital/Galdakao C.S.
Galdakao, Bilbao, Spain - Basauri C.S.
Basauri, Bizkaia, Spain - Hospital Universitario de Basurto
Bilbao, Bizkaia, Spain
|
|
| 13 |
NCT02854033 |
Recruiting |
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol |
- Mild Cognitive Impairment (MCI)
- Alzheimer's Disease (AD)
|
|
Observational |
|
- University of Southern California
- Northern California Institute of Research and Education
- National Institute on Aging (NIA)
- Alzheimer's Therapeutic Research Institute
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Rate of change in cognition as measured by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13)
- Rate of change in cognition as measured by the Logical Memory Test I and II
- Rate of change in cognition as measured by the Mini-Mental State Examinations (MMSE)
- (and 12 more...)
|
2000 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT02854033 |
ATRI-001
U01AG024904 |
ADNI3 |
October 2016 |
October 2021 |
October 2021 |
August 3, 2016 |
May 24, 2018 |
|
- University of Alabama, Birmingham
Birmingham, Alabama, United States - Banner Alzheimer's Institute
Phoenix, Arizona, United States - Barrow Neurological Institute
Phoenix, Arizona, United States - (and 57 more...)
|
|
| 14 |
NCT03132272 |
Recruiting |
Immunoadsorption for Treatment of Alzheimer's Disease |
|
- Device: Immunoadsorption with Globaffin
|
Interventional |
Not Applicable |
- University Medicine Greifswald
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes in cerebral blood flow, estimated by Arterial Spin Labeling MRI
- Cognition (changes/improvement/impairment)
- Vascular effects
- (and 2 more...)
|
15 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT03132272 |
201503IMAD
CIV-16-02-014668 |
IMAD |
June 2016 |
July 2018 |
July 2018 |
April 27, 2017 |
April 27, 2017 |
|
- University Medicine Greifswald
Greifswald, Mecklenburg-Vorpommern, Germany
|
|
| 15 |
NCT02959489 |
Recruiting |
Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN) |
- Alzheimer Disease
- Amyloid Beta-Peptides
- Risk Assessment
- (and 3 more...)
|
- Behavioral: Alzheimer's Disease Risk Disclosure
- Behavioral: Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure
|
Interventional |
Not Applicable |
- Brigham and Women's Hospital
- University of Pennsylvania
- University of Michigan
- (and 3 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Change in baseline neuropsychological performance compared to 6 weeks and 6 months post-disclosure
- Change in baseline measure scores on scales and questionnaires of psychological distress compared to 6 weeks and 6 months post-disclosure.
- Change in baseline measures of health behaviors compared to 6 weeks and 6 months post-disclosure to determine the type and frequency of behavior changes in response to learning risk information.
|
270 |
All |
65 Years to 80 Years (Adult, Senior) |
NCT02959489 |
RF1AG047866
1RF1AG047866-01A1 |
REVEAL-SCAN |
November 2016 |
July 2019 |
July 2019 |
November 9, 2016 |
December 20, 2016 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - University of Michigan
Ann Arbor, Michigan, United States - Duke University
Durham, North Carolina, United States - University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
|
| 16 |
NCT01504958 |
Completed
Has Results |
Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients |
|
- Device: Repetitive Transcranial Magnetic Stimulation (rTMS)
- Behavioral: NICE Cognitive Training
|
Interventional |
Not Applicable |
- Beth Israel Deaconess Medical Center
- Neuronix Ltd
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)
- Clinical Global Impression of Change (CGIC)
- Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL)
|
22 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT01504958 |
2010P000325 |
|
December 2010 |
May 2015 |
May 2015 |
January 6, 2012 |
July 2, 2017 |
June 5, 2017 |
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
|
|
| 17 |
NCT03373604 |
Enrolling by invitation |
Imaging Tau in Alzheimer's Disease and Normal Aging |
|
- Drug: 18F-MK-6240
- Procedure: Lumbar Puncture (optional)
|
Interventional |
Phase 2 |
- William Charles Kreisl
- National Institute on Aging (NIA)
- Columbia University
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- 18F-MK-6240 binding (standardized uptake value ratio)
- Correlation of 18F-MK-6240 binding and CSF markers of neurodegeneration and inflammation.
|
175 |
All |
50 Years to 100 Years (Adult, Senior) |
NCT03373604 |
AAAR4352
K23AG052633-02 |
|
December 11, 2017 |
August 20, 2021 |
August 20, 2021 |
December 14, 2017 |
January 10, 2018 |
|
- Columbia University Medical Center
New York, New York, United States
|
|
| 18 |
NCT02565511 |
Recruiting |
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease |
|
- Biological: CAD106 Immunotherapy
- Other: Placebo to CAD106
- Drug: CNP520
- Other: Placebo to CNP520
|
Interventional |
Phase 2
Phase 3 |
- Novartis Pharmaceuticals
- Banner Alzheimer's Institute
- National Institute on Aging (NIA)
- (and 3 more...)
|
Industry / Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to diagnosis of MCI due to Alzheimer's Disease (AD) or dementia due to Alzheimer's Disease
- Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score
- Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score
- (and 7 more...)
|
1340 |
All |
60 Years to 75 Years (Adult, Senior) |
NCT02565511 |
CAPI015A2201J
2015-002715-15
1UF1AG046150-01 |
Generation S1 |
November 30, 2015 |
August 30, 2024 |
September 2, 2024 |
October 1, 2015 |
May 7, 2018 |
|
- Banner Alzheimer's Institute
Phoenix, Arizona, United States - Mayo Clinic Arizona
Scottsdale, Arizona, United States - Banner Sun City Research Institute
Sun City, Arizona, United States - (and 76 more...)
|
|
| 19 |
NCT01796314 |
Completed |
Impact of Therapeutic Educational Programme on the Alzheimer's Disease Affected Patient's Quality of Life |
|
- Behavioral: Therapeutic Educational Program
|
Interventional |
Not Applicable |
- University Hospital, Toulouse
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Supportive Care
|
- Quality of life
- Caregiver quality of life
|
170 |
All |
50 Years to 100 Years (Adult, Senior) |
NCT01796314 |
11 255 07
PREQHOS n°11 255 07 |
THERAD |
January 2013 |
February 2017 |
February 2017 |
February 21, 2013 |
November 1, 2017 |
|
- CHU de Toulouse, Hôtel-Dieu, 2 rue Viguerie
Toulouse, France
|
|
| 20 |
NCT02208193 |
Unknown † |
Alzheimer's Disease, Art and Garden |
|
- Behavioral: Cognitive and psycho-behavioral effects of an artistic dimension
|
Interventional |
Not Applicable |
- Central Hospital, Nancy, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Comparaison of the number of language acts in each category between AD and controls subjects
- Scores obtained in standard neuropsychological tests, in particular to assess spatio-temporal orientation (Folstein MMSE),
- Scores obtained with the " MemoArtZ " tool (MAZ) to evaluate the memorization of artistic elements of the garden,
- (and 3 more...)
|
60 |
All |
60 Years and older (Adult, Senior) |
NCT02208193 |
2014-A00139-38 |
JAZ ART |
July 2014 |
October 2016 |
September 2017 |
August 4, 2014 |
July 30, 2015 |
|
|
|
| 21 |
NCT00987090 |
Unknown † |
Early-onset and Late-onset Sporadic Alzheimer's Disease (AD) |
|
- Biological: Clinic and neuropsychologic evaluation
- Radiation: MRI
- Procedure: PET
- (and 2 more...)
|
Interventional |
Not Applicable |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- to establish the impact of age on the clinical and neuroimaging picture of sporadic Alzheimer Disease in a multicentric setting.
- to describe for each age group, and in particular for the younger patient group, the functional impact of disability in everyday life on both, patients and caregivers.
|
240 |
All |
45 Years to 90 Years (Adult, Senior) |
NCT00987090 |
2008/24
2008-A01213-52 |
|
October 2009 |
September 2016 |
|
September 30, 2009 |
October 23, 2015 |
|
- Assistance Publique - Hôpitaux de Marseille
Marseille, France
|
|
| 22 |
NCT00412048 |
Withdrawn |
Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease |
|
- Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease
|
Interventional |
Not Applicable |
- University Hospital, Strasbourg, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Comparing fMRI data between 3 groups of subjects: MCI, Alzheimer's disease and normal subjects
- Follow-up of MCI patients at 6, 12 and 18 months to detect a conversion to Alzheimer's disease
|
0 |
All |
55 Years to 75 Years (Adult, Senior) |
NCT00412048 |
3659 |
|
April 2012 |
February 2018 |
February 2018 |
December 15, 2006 |
November 14, 2012 |
|
|
|
| 23 |
NCT01850238 |
Completed |
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease |
|
- Biological: AADvac1
- Other: Placebo
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Tolerability and safety profile of AADvac1 in patients with mild-to-moderate Alzheimer's disease
- Immunogenicity of AADvac1
|
30 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT01850238 |
AXON CO 18700
2012-003916-29 |
|
May 2013 |
March 2015 |
March 2015 |
May 9, 2013 |
October 12, 2015 |
|
- Medizinische Universitat Graz
Graz, Steiermark, Austria - Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik
Salzburg, Austria - Medizinische Universitat Wien
Wien, Austria
|
|
| 24 |
NCT01928420 |
Completed |
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease |
- Alzheimer's Disease
- Dementia
|
- Drug: Drug: NIC5-15
- Drug: Placebo
|
Interventional |
Phase 2 |
- Humanetics Corporation
- National Center for Complementary and Integrative Health (NCCIH)
- James J. Peters Veterans Affairs Medical Center
|
Industry / NIH / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score
- Change in Alzheimer's Disease Cooperative Study Clinician's Global Impression of Change (ADCS-CCGIC) Score
- Change in Mini-Mental State Examination (MMSE) Score
- (and 4 more...)
|
30 |
All |
40 Years to 95 Years (Adult, Senior) |
NCT01928420 |
R21AT003302-01A1
MHBB-009-06S |
|
April 2007 |
June 2014 |
June 2014 |
August 26, 2013 |
October 17, 2016 |
|
- James J Peters Veterans Affairs Medical Center
Bronx, New York, United States
|
|
| 25 |
NCT02769000 |
Recruiting |
Low Dose RT to Reduce Cerebral Amyloidosis in Early Alzheimer's |
|
- Radiation: 10 GY in 5 daily fractions
- Radiation: 20 GY in 10 daily fractions
|
Interventional |
Not Applicable |
- Virginia Commonwealth University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate safety and toxicity/adverse events associated with delivery of low dose fractionated whole brain irradiation in subjects with early Alzheimer's dementia according to NINCDS-ADRDA Criteria.
- Evaluate low dose whole brain irradiation in subjects with early Alzheimer's dementia using neurcognitive testing methods.
- Evaluate low dose whole brain irradiation in subjects with early Alzheimer's dementia using psychological functioning tests.
- Evaluate low dose whole brain irradiation in subjects with early Alzheimer's dementia using Quality of Life indices.
|
30 |
All |
55 Years and older (Adult, Senior) |
NCT02769000 |
HM20004955 |
|
May 2016 |
April 2019 |
April 2019 |
May 11, 2016 |
March 29, 2018 |
|
- Virginia Commonwealth University
Richmond, Virginia, United States
|
|
| 26 |
NCT03055741 |
Recruiting |
Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil |
- Mild-moderate Alzheimer's Disease
|
- Drug: Donepezil
- Drug: DHP1401
- Drug: Placebo
|
Interventional |
Phase 2 |
- Daehwa Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale-cognition Korean version(ADAS-cog)
- Clinical Dementia Rating Sum of Box Korean version(CDR-SB)
- Neuropsychiatric Inventory-Q Korean version(NPI-Q)
- (and 3 more...)
|
180 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT03055741 |
1401CS-2 |
|
December 28, 2016 |
September 2018 |
September 2018 |
February 16, 2017 |
December 4, 2017 |
|
- The Catholic University of Korea, Bucheon, ST. Mary's Hospital
Bucheon-si, Gyeonggi-do, Korea, Republic of - Myongji Hospital
Goyang-si, Gyeonggi-do, Korea, Republic of - Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, Korea, Republic of - (and 8 more...)
|
|
| 27 |
NCT03090854 |
Not yet recruiting |
Cholinergic Markers Alzheimer's Disease |
|
|
Observational |
|
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Neuropsychological test (ADASCog)
- Rate of responder AD in this cohort included according to the new AD criteria and comparison of the current rate with the previous rate published using former AD criteria
- Difference of CSF Ach AND AChE activity between responder and non responder groups
- Statistical evaluation of the link between CSF Ach, AChE activity, total and phosphorylated Tau, Aß40 and Aß42.
|
100 |
All |
50 Years and older (Adult, Senior) |
NCT03090854 |
K160402
2016-AO1639-42 |
CHOLINE |
September 1, 2017 |
September 1, 2019 |
September 1, 2019 |
March 27, 2017 |
August 29, 2017 |
|
- Centre Mémoire de Ressources et de Recherche Paris Nord
Paris, France
|
|
| 28 |
NCT03507257 |
Not yet recruiting |
Longitudinal Early-onset Alzheimer's Disease Study Protocol |
- Early Onset Alzheimer Disease
- Alzheimer Disease
- Mild Cognitive Impairment
|
- Drug: Flortaucipir
- Drug: Florbetaben
|
Observational |
|
- Liana Apostolova
- Alzheimer's Therapeutic Research Institute
- National Institute on Aging (NIA)
- (and 2 more...)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Rate of change in cognition as measured by by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13)
- Rate of change in cognition as measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB)
- Rate of change in cognition as measured by the Clinician Judgment of Symptoms form from the NACC UDS.
- (and 5 more...)
|
500 |
All |
40 Years to 64 Years (Adult) |
NCT03507257 |
ATRI-003
R56AG057195 |
LEADS |
May 1, 2018 |
August 31, 2022 |
August 31, 2023 |
April 25, 2018 |
April 25, 2018 |
|
|
|
| 29 |
NCT01399125 |
Completed
Has Results |
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease |
|
- Drug: Rivastigmine Patch
- Drug: Rivastigmine Capsules
- Drug: Placebo to Rivastigmine patch
- Drug: Placebo to Rivastigmine capsules
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline on Cognition, Assessed by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)
- Change From Baseline in Global Functioning, Assessed by the Alzheimer's Disease Assessment Scale Clinical Impression of Change (ADCS-CGIC)
- Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Total Score
- (and 2 more...)
|
501 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT01399125 |
CENA713D2344 |
|
July 2011 |
May 2013 |
May 2013 |
July 21, 2011 |
August 4, 2014 |
August 4, 2014 |
- Novartis Investigative Site
Fuzhou, Fujian, China - Novartis Investigative Site
Wuhan, Hubei, China - Novartis Investigative Site
Wuhan, Hubei, China - (and 13 more...)
|
|
| 30 |
NCT02769234 |
Enrolling by invitation |
EEG/ERP Longitudinal Study in Alzheimer's Disease (AD) |
|
- Procedure: ERP/EEG test
- Procedure: Psychometric testing
|
Observational |
|
- Neuronetrix, Inc.
- Boston Center for Memory
- The Memory Clinic of Vermont
- Premiere Research Institute
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Correlation (longitudinal change) between EEG/ERP vs. Neuropsychological Testing.
- Correlation (longitudinal change) between EEG/ERP vs ADNI-EF composite.
- Correlation (longitudinal change) between EEG/ERP vs. ADNI-Mem composite.
|
75 |
All |
60 Years to 95 Years (Adult, Senior) |
NCT02769234 |
SRP-1782 |
|
May 2016 |
June 2017 |
July 2017 |
May 11, 2016 |
May 30, 2017 |
|
- Premiere Research Institute
West Palm Beach, Florida, United States - Boston Center for Memory
Brookline, Massachusetts, United States - The Memory Clinic
Bennington, Vermont, United States
|
|
| 31 |
NCT02031198 |
Completed |
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease |
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tolerability and safety profile of AADvac1 in patients with mild-to-moderate Alzheimer's disease
- Immunogenicity of AADvac1
- Patient cognition
|
25 |
All |
50 Years to 86 Years (Adult, Senior) |
NCT02031198 |
AC-AD-002
2013-004499-36 |
FUNDAMANT |
January 2014 |
August 2016 |
December 2016 |
January 9, 2014 |
March 17, 2017 |
|
- Medizinische Universitat Graz
Graz, Steiermark, Austria - Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik
Salzburg, Austria - Medizinische Universitat Wien
Wien, Austria - Sozialmedizinisches Zentrum Ost (SMZ Ost) /Donauspital, Memory Clinic and Karl Landsteiner Institut for Amnestic disorders
Wien, Austria
|
|
| 32 |
NCT02702817 |
Completed |
Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia |
- Alzheimer Disease
- Cognitive Decline Due to Alzheimer Disease
- Mild Cognitive Impairment Due to Alzheimer Disease
|
- Drug: Naproxen
- Drug: Placebo
|
Interventional |
Phase 2 |
- Douglas Mental Health University Institute
- McGill University
- Johns Hopkins University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Trajectory of composite Alzheimer Progression Score (APS) from multiple cognitive and biomarker measures of pre-clinical Alzheimer's disease
- frequency and severity of treatment-emergent adverse events
- trajectory of cognitive abilities measured by global score on Repeatable Battery for Assessment of Neuropsychological Status
- (and 3 more...)
|
200 |
All |
55 Years and older (Adult, Senior) |
NCT02702817 |
INTREPAD |
|
August 1, 2012 |
March 31, 2017 |
July 15, 2017 |
March 9, 2016 |
August 1, 2017 |
|
- Douglas Hospital Research Centre
Montreal, Quebec, Canada
|
|
| 33 |
NCT02253043 |
Recruiting |
The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Alzheimer's Disease |
|
- Device: Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)
|
Interventional |
Not Applicable |
- Beijing Pins Medical Co., Ltd
- Beijing Tiantan Hospital
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog)
- Clinical Dementia Rating Scale
|
10 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT02253043 |
PINS-002 |
|
May 2014 |
December 2018 |
December 2018 |
October 1, 2014 |
October 14, 2016 |
|
- Beijing Tiantan Hospital
Beijing, Beijing, China - 301 Hospatl
Beijing, Beijing, China
|
|
| 34 |
NCT00973518 |
Completed |
Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG) |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Identification and characterization of patterns of correlated brain activity measured by MEG and the Orasi SNI test that differ consistently (e.g. at all evaluation time points) between HC and AD subjects
- Identification and characterization of patterns of correlated brain activity measured by MEG and the Orasi SNI test that differ across time points within single subjects and across groups of HC and AD subjects
- Identification and characterization of Orasi SNI test features that correlate with independent measures of cognitive function based on functional testing (ADAS-Cog sum of boxes, and MMSE raw score, One Card Learning Test)
- (and 2 more...)
|
160 |
All |
50 Years to 90 Years (Adult, Senior) |
NCT00973518 |
ADD 09-02 |
|
September 2009 |
June 2010 |
June 2010 |
September 9, 2009 |
August 13, 2010 |
|
- Rush Alzheimer's Disease Center
Chicago, Illinois, United States - Alexian Brothers Neuroscience Institute
Elk Grove Village, Illinois, United States
|
|
| 35 |
NCT02007291 |
Completed |
Good Rate of Clinical Response to Cholinesterase Inhibitors in Alzheimer's Disease After Three Months of Treatment |
|
|
Observational |
|
- Federal University of Minas Gerais
|
Other |
- Time Perspective: Prospective
|
- MMSE scores at three, six and twelve months indicate response to ChEI in mild and moderate Alzheimer's disease
- Good rate of cognitive response to cholinesterase inhibitors after 3 months of treatment
|
97 |
All |
59 Years to 93 Years (Adult, Senior) |
NCT02007291 |
0172 / 2010 |
NINDS-AIREN |
June 2010 |
March 2013 |
March 2013 |
December 10, 2013 |
December 10, 2013 |
|
|
|
| 36 |
NCT01887899 |
Active, not recruiting |
Influence of tDCS on Cortical Plasticity in Patients With Dementia of the Alzheimer Type |
- Dementia of Type Alzheimer
|
- Device: transcranial direct current stimulation
- Device: sham stimulation
|
Interventional |
Not Applicable |
- Charite University, Berlin, Germany
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- the anodal transcranial direct current stimulation over the primary motor cortex (M1) in patients with dementia of Alzheimer type (DAT)
- tDCS effects on central cholinergic activity in patients with DAT
- tDCS effects on learning
- (and 2 more...)
|
15 |
All |
50 Years to 80 Years (Adult, Senior) |
NCT01887899 |
Plasticity in Alzheimer's |
|
May 2013 |
October 2017 |
December 2017 |
June 27, 2013 |
December 22, 2016 |
|
- Klinik und Poliklinik für Neurologie, Charité Universitätsmedizin Berlin
Berlin, Germany
|
|
| 37 |
NCT02158910 |
Completed |
A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients |
|
|
Observational |
|
- Eisai Korea Inc.
- Eisai Inc.
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Safety and tolerability due to an increase of Aricept in patients with Alzheimer's disease.
|
2231 |
All |
Child, Adult, Senior |
NCT02158910 |
ART-M082-601 |
AID |
March 2015 |
June 2016 |
June 2016 |
June 9, 2014 |
March 7, 2017 |
|
- Busan, Korea, Republic of
- Chungcheongbuk-do, Korea, Republic of
- Chungcheongnam-do, Korea, Republic of
- (and 10 more...)
|
|
| 38 |
NCT02958930 |
Enrolling by invitation |
Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease |
- Alzheimer Disease
- Alzheimer Disease, Late Onset
|
|
Interventional |
Phase 1 |
- NeuroEM Therapeutics, Inc.
- Byrd Alzheimer's Institute, University of South Florida
- University Diagnostic Institute, Tampa
- Arizona State University
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- ADAS-Cog
- FDG-PET
- Resting state fMRI
- (and 15 more...)
|
12 |
All |
63 Years and older (Adult, Senior) |
NCT02958930 |
NeuroEM-001
EM 1000-1 |
|
October 1, 2017 |
August 2018 |
August 2018 |
November 8, 2016 |
March 29, 2018 |
|
- Byrd Alzheimer's Institute, University of South Florida
Tampa, Florida, United States
|
|
| 39 |
NCT02864303 |
Recruiting |
Use of Saliva for Alzheimer's Disease Diagnosis |
- Alzheimer's Disease
- Mild Cognitive Impairment
|
|
Interventional |
Not Applicable |
- University Hospital, Montpellier
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Aβ40 and Aβ42
- Neuropsychologic tests
- ApoE polymorphism
|
250 |
All |
55 Years to 80 Years (Adult, Senior) |
NCT02864303 |
8835 |
SalivALZ |
June 2012 |
December 2018 |
December 2018 |
August 12, 2016 |
December 22, 2016 |
|
|
|
| 40 |
NCT01609348 |
Completed
Has Results |
Venlafaxine for Depression in Alzheimer's Disease (DIADs-3) |
- Alzheimer's Disease
- Depression
|
- Drug: Placebo
- Drug: Venlafaxine
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Changes in Dose Response Using the Modified Alzheimer's Disease (AD) Cooperative Study-Clinical Global Impression of Change.
|
5 |
All |
Child, Adult, Senior |
NCT01609348 |
NA_00066043 |
DIADs-3 |
April 2012 |
December 2016 |
January 2017 |
June 1, 2012 |
January 31, 2018 |
January 31, 2018 |
- Johns Hopkins at Bayview
Baltimore, Maryland, United States - Reading Hospital
West Reading, Pennsylvania, United States
|
|
| 41 |
NCT01466088 |
Completed |
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD) |
|
- Drug: Donepezil
- Drug: AZD3480
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog)
- Change from baseline in the Clinician Interview-Based Impression of Change plus carer interview [CIBIC-(+)]
- Change from baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)
- (and 3 more...)
|
386 |
All |
60 Years to 85 Years (Adult, Senior) |
NCT01466088 |
TC-1734-226-CRD-006 |
|
October 2011 |
May 2014 |
May 2014 |
November 7, 2011 |
June 3, 2015 |
|
- Banner Alzheimer Institute
Phoenix, Arizona, United States - Meridien Research
Brooksville, Florida, United States - MD Clinical
Hallandale Beach, Florida, United States - (and 30 more...)
|
|
| 42 |
NCT00818662 |
Completed
Has Results |
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease |
|
- Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg
- Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg
- Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg
- Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg
|
Interventional |
Phase 3 |
- Baxalta now part of Shire
- Alzheimer's Disease Cooperative Study (ADCS)
- Shire
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)
- Change From Baseline at 18 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
- Change From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)
- (and 24 more...)
|
390 |
All |
50 Years to 89 Years (Adult, Senior) |
NCT00818662 |
160701 |
|
December 2008 |
December 2012 |
December 2012 |
January 8, 2009 |
November 24, 2017 |
October 28, 2014 |
- Birmingham, Alabama, United States
- Phoenix, Arizona, United States
- Sun City, Arizona, United States
- (and 38 more...)
|
|
| 43 |
NCT01883648 |
Terminated |
Study to Evaluate Coconut Oil for Alzheimer's Disease |
|
- Drug: Coconut Oil Beverage
- Other: Placebo Beverage
|
Interventional |
Phase 2
Phase 3 |
- University of South Florida
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline to Month 3 of each treatment phase (a 3 month period of time) in cognitive testing (ADAS-cog, MMSE, Category/Letter Fluency)
- Change from baseline to Month 3 of each treatment phase (a 3 month period of time) in Trails A & B cognitive testing
- Change from baseline to Month 3 of each treatment phase (a 3 month period of time) on Geriatric Depression Scale
- (and 4 more...)
|
21 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT01883648 |
Byrd AD-001 |
|
June 2013 |
February 1, 2017 |
February 1, 2017 |
June 21, 2013 |
April 28, 2017 |
|
- USF Health Byrd Alzheimer's Institute
Tampa, Florida, United States
|
|
| 44 |
NCT01311492 |
Completed |
Exercise Trial for Alzheimer's Disease |
|
- Behavioral: Healthy Lifestyle Program
- Behavioral: Physical Activity Intervention
|
Interventional |
Not Applicable |
- Pennington Biomedical Research Center
- St. James Place of Baton Rouge
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Effect of exercise on cognitive decline
- Measuring the effects of exercise on depression, metabolic indices, and changes in overall function.
- Evidence based feasibility for conducting exercise interventions in the Alzheimer's Disease population.
|
10 |
All |
65 Years and older (Adult, Senior) |
NCT01311492 |
PBRC10035 |
EXTRA |
March 2011 |
April 2013 |
April 2013 |
March 9, 2011 |
May 27, 2013 |
|
- Programs of All-Inclusive Care for the Elderly (PACE)
Baton Rouge, Louisiana, United States - Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States
|
|
| 45 |
NCT02839187 |
Completed |
Neuro Imaging and Multimodal Alzheimer's Disease |
|
|
Interventional |
Not Applicable |
- University Hospital, Toulouse
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- fixing the AV-45 during PET
- Deposition of amyloid protein
- Standard Cognitive function
- Specific memory evaluation
|
59 |
All |
60 Years to 85 Years (Adult, Senior) |
NCT02839187 |
07 306 02 |
NIMAD |
June 2010 |
May 2012 |
May 2012 |
July 20, 2016 |
May 11, 2017 |
|
- University Hospital of Toulouse
Toulouse, France
|
|
| 46 |
NCT02947893 |
Recruiting |
Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease |
|
- Drug: Placebo Capsule(s) Once a Day by Mouth
- Drug: Nilotinib Capsule(s) Once a Day by Mouth
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety will be measured by number of participants experiencing the occurrence of adverse events and/or abnormal laboratory values
- Effects of Nilotinib treatment on measurement of Nilotinib in the CSF
|
42 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT02947893 |
2016-0315 |
AD |
January 2017 |
February 2019 |
December 2019 |
October 28, 2016 |
February 20, 2018 |
|
- Georgetown University Medical Center
Washington, District of Columbia, United States
|
|
| 47 |
NCT01409915 |
Active, not recruiting |
Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease |
|
- Drug: Sagramostim
- Drug: Saline -- placebo comparator
|
Interventional |
Phase 2 |
- University of Colorado, Denver
- The Dana Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Ability of Alzheimer's Disease subjects to tolerate Leukine treatment will be assessed
- Ability of Leukine treatment to improve cognition of Alzheimer's Disease subjects
|
40 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT01409915 |
12-1273 |
|
March 2011 |
November 2018 |
November 2018 |
August 4, 2011 |
January 18, 2018 |
|
- University of Colorado Denver, Anschutz Medical Campus
Aurora, Colorado, United States
|
|
| 48 |
NCT01926249 |
Active, not recruiting |
A Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders |
- Alzheimer's Disease (AD) and Related Disorders
|
|
Observational |
|
- University Hospital, Bordeaux
- Fondation Plan Alzheimer
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Progression to clinical dementia stage according to standardized classifications (DSM-IV for dementia and NINCDS-ADRDA for Alzheimer's disease)
- Mortality
- Loss of autonomy based on functional activity assessment
- (and 6 more...)
|
2300 |
All |
18 Years and older (Adult, Senior) |
NCT01926249 |
CHUBX 2010/47 |
MEMENTO |
April 2011 |
June 2019 |
June 2019 |
August 20, 2013 |
April 6, 2017 |
|
- CHU d'Amiens
Amiens, France - CHU d'Angers
Angers, France - CHU de Besançon
Besancon, France - (and 26 more...)
|
|
| 49 |
NCT02638519 |
Recruiting |
HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease |
|
- Other: Traditional Proton fMRI
- Other: Hyperpolarized Xenon-129 fMRI
- Drug: Hyperpolarized Xenon-129
- Device: 1H-129Xe Dual-Tuned Quadrature Head Coil
|
Interventional |
Early Phase 1 |
- Thunder Bay Regional Research Institute
- Lakehead University
- Thunder Bay Regional Health Sciences Centre
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Signal-to-Noise Ratio (SNR)
- P-Value
|
120 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT02638519 |
RP-307-08312015 |
|
June 2016 |
June 2019 |
June 2019 |
December 23, 2015 |
November 17, 2017 |
|
- Thunder Bay Regional Health Sciences Centre
Thunder Bay, Ontario, Canada
|
|
| 50 |
NCT02279511 |
Completed |
ATP in Alzheimer Disease |
|
- Drug: ADENOSINE TRIPHOSPHATE
- Drug: PLACEBO
|
Interventional |
Phase 2 |
- Sara Varea
- Fundacion Clinic per a la Recerca Biomédica
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Other
|
- Detection of brain metabolic changes after ATP infusion by spectroscopy techniques (H + MRS)
- Changes in Cogstate results
- Changes in test Mini-Mental State Examination
- (and 3 more...)
|
20 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT02279511 |
ECA4A |
|
December 2014 |
February 2016 |
February 2016 |
October 31, 2014 |
March 29, 2017 |
|
- Fundació ACE
Barcelona, Spain - Hospital Sanitas CIMA
Barcelona, Spain
|
|
Create an RSS feed from your search for:
Download the search results for: